Clinical Trial Detail

NCT ID NCT01751451
Title 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate cancer

Therapies

Abiraterone

Degarelix

Age Groups: adult

No variant requirements are available.